40 27

Cited 0 times in

Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer

Authors
 Yong Jun Lee  ;  Jii Bum Lee  ;  Sang-Jun Ha  ;  Hye Ryun Kim 
Citation
 MOLECULES AND CELLS, Vol.44(5) : 363-373, 2021-05 
Journal Title
MOLECULES AND CELLS
ISSN
 1016-8478 
Issue Date
2021-05
Keywords
acquired resistance ; immune checkpoint inhibitors ; non-small cell lung cancer ; programmed death ligand-1 ; programmed death-1
Abstract
Immune checkpoint inhibitors have changed the paradigm of treatment options for non-small cell lung cancer (NSCLC). Monoclonal antibodies targeting programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have gained wide attention for their application, which has been shown to result in prolonged survival. Nevertheless, only a limited subset of patients show partial or complete response to PD-1 therapy, and patients who show a response eventually develop resistance to immunotherapy. This article aims to provide an overview of the mechanisms of acquired resistance to anti-PD-1/PD-L1 therapy from the perspective of tumor cells and the surrounding microenvironment. In addition, we address the potential therapeutic targets and ongoing clinical trials, focusing mainly on NSCLC.
Files in This Item:
T202101784.pdf Download
DOI
10.14348/molcells.2021.0044
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Hye Ryun(김혜련) ORCID logo https://orcid.org/0000-0002-1842-9070
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/183977
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links